RESUMEN
We previously showed that supplementation of a high fat diet with paramylon (PM) reduces the postprandial glucose rise, serum total and LDL cholesterol levels, and abdominal fat accumulation in mice. The purpose of this study was to explore the underlying mechanism of PM using microarray analysis. Male mice (C57BL/BL strain) were fed an experimental diet (50% fat energy) containing 5% PM isolated from Euglena gracilis EOD-1 for 12 weeks. After confirming that PM had an improving effect on lipid metabolism, we assessed ileal and hepatic mRNA expression using DNA microarray and subsequent analysis by gene ontology (GO) classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The results suggested that dietary supplementation with PM resulted in decreased abdominal fat accumulation and serum LDL cholesterol concentrations via suppression of the digestion and absorption pathway in the ileum and activation of the hepatic PPAR signaling pathway. Postprandial glucose rise was reduced in mice fed PM, whereas changes in the glucose metabolism pathway were not detected in GO classification and KEGG pathway analysis. PM intake might enhance serum secretory immunoglobulin A concentrations via promotion of the immunoglobulin production pathway in the ileum.
Asunto(s)
Suplementos Dietéticos , Glucanos/administración & dosificación , Íleon/metabolismo , Metabolismo de los Lípidos , Hígado/metabolismo , Obesidad/metabolismo , Grasa Abdominal/metabolismo , Animales , Glucemia/metabolismo , Peso Corporal , Dieta , Ingestión de Alimentos , Euglena gracilis/química , Regulación de la Expresión Génica , Ontología de Genes , Glucanos/química , Glucanos/aislamiento & purificación , Glucanos/farmacología , Inmunoglobulina A Secretora/sangre , Lípidos/sangre , Masculino , Redes y Vías Metabólicas/genética , Ratones , Ratones Endogámicos C57BL , Análisis de Secuencia por Matrices de Oligonucleótidos , Tamaño de los Órganos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transducción de Señal/genéticaRESUMEN
Japanese Cedar (JC) pollinosis is the most common seasonal allergic rhinitis in Japan. Throughout the JC pollen season, patients suffer from the allergic symptoms, resulting in a reduction of quality of life. Allergy immunotherapy (AIT) is an established treatment option for a wide range of allergens that unlike symptomatic treatments (e.g. antihistamines) may provide sustained immune tolerance. However, AIT, especially subcutaneous immunotherapy (SCIT) has a fatal anaphylaxis risk due to the use of crude allergen extracts. Consequently, development of allergen derivatives with substantially reduced anaphylactic potential is desirable. An allergen derivative that showed reduced IgE-binding and anaphylactic potential was developed through conjugation of native Cry j 1 (n Cry j 1), a major JC allergen, to the polysaccharide pullulan followed by chemical but non-covalent denaturation. The resulting Cry j 1 allergen derivative, Dn p-Cry j 1, showed reduced IgE-binding and IgE-mediated effector cell activation in vitro using an ELISA competition assay and a mast cell activation model (EXiLE). Reduced anaphylactic potential of Dn p-Cry j 1 in vivo was demonstrated using the rat passive cutaneous anaphylaxis (PCA) assay. The difference in anaphylactic potential of Dn p-Cry j 1 compared to n Cry j 1 in wild-type rats was of the same magnitude as the difference seen in the anaphylaxis reactions obtained with n Cry j 1 in wild-type rats and mast-cell deficient rats, indicating a dramatic reduction in anaphylactic potential of Dn p-Cry j 1. These results indicate that Dn p-Cry j 1 is a promising candidate for next-generation JC AIT.
Asunto(s)
Antígenos de Plantas/administración & dosificación , Desensibilización Inmunológica/métodos , Glucanos/administración & dosificación , Proteínas de Plantas/administración & dosificación , Rinitis Alérgica Estacional/terapia , Alérgenos/inmunología , Animales , Antígenos de Plantas/química , Antígenos de Plantas/inmunología , Cryptomeria/inmunología , Modelos Animales de Enfermedad , Glucanos/química , Glucanos/inmunología , Humanos , Mastocitos/inmunología , Ratones , Anafilaxis Cutánea Pasiva , Proteínas de Plantas/química , Proteínas de Plantas/inmunología , Polen/inmunología , Ratas , Rinitis Alérgica Estacional/sangre , Rinitis Alérgica Estacional/diagnóstico , Rinitis Alérgica Estacional/inmunologíaRESUMEN
Euglena gracilis is widely utilized as food or supplement to promote human and animal health, as it contains rich nutrients. In this study, we administered spray-dried powder of E. gracilis and paramylon, ß-glucan stored in E. gracilis cells, to A4gnt knockout (KO) mice. A4gnt KO mice are a mutant mouse model that spontaneously develops gastric cancer through hyperplasia-dysplasia-adenocarcinoma sequence in the antrum of the stomach, and we observed the effects of E. gracilis and paramylon on the early involvements of A4gnt KO mice. Male and female 10-week-old A4gnt KO mice and their age-matched wildtype C57BL/6J mice were orally administered with 50 mg of E. gracilis or paramylon suspended in saline or saline as a control. After 3-week administration, animals were euthanatized and the stomach was examined histopathologically and immunohistochemically. Gene expression patterns of the stomach, which have been reported to be altered with A4gnt KO, and IgA concentration in small intestine were also analyzed with real-time PCR and ELISA, respectively. Administration of Euglena significantly reduced the number of stimulated CD3-positive T-lymphocytes in pyloric mucosa of A4gnt KO mice and tend to reduce polymorphonuclear leukocytes infiltration. Euglena administration further downregulated the expression of Il11 and Cxcl1 of A4gnt KO mice. Euglena administration also affected IgA concentration in small intestinal contents of A4gnt KO mice. Paramylon administration reduced the number of CD3-positive lymphocytes in pyloric mucosa of A4gnt KO mice, and downregulated the expressions of Il11 and Ccl2 of A4gnt KO mice. Although we found no significant effects on gross and microscopic signs of gastric dysplasia and cell proliferation, the present study suggests that the administration of Euglena and paramylon may ameliorate the early involvements of A4gnt mice through the effects on inflammatory reactions in the gastric mucosa. The cancer-preventing effects should be studied with long-term experiments until actual gastric cancer formation.
Asunto(s)
Anticarcinógenos/uso terapéutico , Euglena gracilis , Glucanos/uso terapéutico , N-Acetilglucosaminiltransferasas/genética , Neoplasias Gástricas/prevención & control , Administración Oral , Animales , Anticarcinógenos/administración & dosificación , Anticarcinógenos/análisis , Suplementos Dietéticos/análisis , Euglena gracilis/química , Femenino , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/patología , Glucanos/administración & dosificación , Glucanos/análisis , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neoplasias Gástricas/genética , Neoplasias Gástricas/patologíaRESUMEN
Constipation is a frequent problem in children. We evaluated the effect of a mixture (polydextrose [PDX] and fructooligosaccharide [FOS]) in children with constipation. We performed a prospective interventional study with a mixture (PDX 4.17 g and FOS 0.45 g) in a daily dose of food supplement. The intervention lasted 45 days, with visits at 15, 30, and 45 days after administration. The sample comprised 105 patients, of whom 77 completed the intervention. A statistically significant reduction in the frequency of symptoms was observed at the end of the study. The frequency of children with fewer than three bowel movements per week dropped from 59.7% to 11.7%, and there was a decrease in the frequency of Bristol type 1 and 2 dry stools (68.8% to 7.8%), pain on defecation (79.2% to 10.4%), and fear of defecation (68.8% to 3.9%). The proportion of children with abdominal pain symptoms decreased from 84.2% to 2.6% at the end of the study. A relevant limitation of the present study was the lack of a control group treated with placebo. The administration of the PDX/FOS mixture was accompanied by a significant reduction in the frequency of constipation symptoms of the children evaluated. The tolerability was very good, and the rate of adverse effects was low.
Asunto(s)
Estreñimiento/dietoterapia , Suplementos Dietéticos , Glucanos/uso terapéutico , Oligosacáridos/uso terapéutico , Niño , Preescolar , Fibras de la Dieta/administración & dosificación , Fibras de la Dieta/uso terapéutico , Quimioterapia Combinada , Femenino , Glucanos/administración & dosificación , Humanos , Masculino , Oligosacáridos/administración & dosificaciónRESUMEN
The objective of this study was to examine the effects of feeding laminarin (LAM) and fucoidan (FUC) enriched seaweed extracts up to d35 post-weaning on measures of animal performance, intestinal microbial and transcriptome profiles. 75 pigs were assigned to one of three groups: (1) basal diet; (2) basal diet + 250 ppm fucoidan; (3) basal diet + 300 ppm laminarin with 7 replicates per treatment group. Measures of performance were collected weekly and animals sacrificed on d35 post-weaning for the sampling of gastrointestinal tissue and digesta. Animal performance was similar between the basal group and the groups supplemented with FUC and LAM (P > 0.05). Pigs fed the basal diet had higher alpha diversity compared to both the LAM and FUC supplemented pigs (P < 0.05). Supplementation with LAM and FUC increased the production of butyric acid compared to basal fed pigs (P < 0.05). At genus level pigs fed the LAM supplemented diet had the greatest abundance of Faecalbacterium, Roseburia and the lowest Campylobacter of the three experimental treatments (P< 0.05). While neither extract had beneficial effects on animal performance, LAM supplementation had a positive influence on intestinal health through alterations in the gastrointestinal microbiome and increased butyrate production.
Asunto(s)
Bacterias/crecimiento & desarrollo , Suplementos Dietéticos , Microbioma Gastrointestinal , Glucanos/administración & dosificación , Intestinos/microbiología , Polisacáridos/administración & dosificación , Algas Marinas/metabolismo , Sus scrofa/microbiología , Factores de Edad , Alimentación Animal , Animales , Bacterias/clasificación , Bacterias/metabolismo , Butiratos/metabolismo , Glucanos/aislamiento & purificación , Valor Nutritivo , Polisacáridos/aislamiento & purificación , Sus scrofa/crecimiento & desarrollo , Sus scrofa/metabolismo , DesteteRESUMEN
Capsaicin (CAP) is the main pungent component in capsicum fruits. Eating too much CAP leads to gastrointestinal injury. Previously, Qingke ß-glucan combined with ß-glucan-utilizing Lactobacillus plantarum S58 (LP.S58) ameliorated high fat-diet-induced obesity, but their effects on CAP-induced gastrointestinal injury have not been investigated. Our results showed that Qingke ß-glucan reduced the CAP-induced gastrointestinal injury in Kunming mice. The serum levels of inflammatory cytokines and gastrointestinal hormones, and the localized inflammation and the expression of EGF, EGFR, VEGF, and ZO-1 in the gastrointestinal tissues in CAP-treated mice were partly restored by Qingke ß-glucan. The CAP-induced increase in the abundances of proinflammatory intestinal bacteria was also reduced by Qingke ß-glucan. More importantly, we found that these beneficial effects of Qingke ß-glucan were markedly enhanced by ß-glucan-utilizing LP.S58 supplementation. Our study indicated that Qingke ß-glucan coupled with ß-glucan-utilizing LP.S58 relieved CAP-induced gastrointestinal injury.
Asunto(s)
Capsaicina/efectos adversos , Gastroenteritis/terapia , Glucanos/administración & dosificación , Hordeum/química , Lactobacillus plantarum/fisiología , Probióticos/administración & dosificación , Animales , Terapia Combinada , Citocinas/sangre , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Receptores ErbB/genética , Receptores ErbB/metabolismo , Gastroenteritis/inducido químicamente , Gastroenteritis/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Redes Reguladoras de Genes/efectos de los fármacos , Glucanos/metabolismo , Glucanos/farmacología , Lactobacillus plantarum/metabolismo , Masculino , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/metabolismo , Extractos Vegetales/farmacología , Probióticos/farmacología , Resultado del Tratamiento , Proteína de la Zonula Occludens-1/genética , Proteína de la Zonula Occludens-1/metabolismoRESUMEN
The goal of this work was to assess the usability of yeast glucan particles (GPs) as carriers for curcumin and determine the beneficial effect of a pharmacological composite of curcumin in GPs on dextran sulfate sodium induced colitis in rats. The assessment of the anti-inflammatory effect of particular substances was evaluated on the basis of the calculated disease activity index and by assessment of cytokines and enzymes from the gut tissue - tumor necrosis factor α (TNF-α), transforming growth factor ß1, interleukin (IL)-1ß, IL-6, IL-10, IL-17, catalase, superoxide dismutase 2, myeloperoxidase (MPO), and matrix metalloproteinase 9. Composites of GPs with incorporated curcumin showed promising results with the capability to lower symptoms of colitis and significantly decrease the production of pro-inflammatory cytokines TNF-α, IL-1ß, IL-6, and the activity of MPO, as well. The anti-inflammatory effect of the composites was greater than those of pure GPs or curcumin.
Asunto(s)
Antiinflamatorios/uso terapéutico , Colitis/tratamiento farmacológico , Curcumina/uso terapéutico , Portadores de Fármacos/uso terapéutico , Glucanos/uso terapéutico , Animales , Antiinflamatorios/administración & dosificación , Colitis/inducido químicamente , Curcumina/administración & dosificación , Citocinas/metabolismo , Sulfato de Dextran , Glucanos/administración & dosificación , Interleucinas/metabolismo , Masculino , Ratas , Ratas Wistar , Saccharomyces cerevisiae/metabolismoRESUMEN
A new amphiphilic pullulan derivative (DBAP-PO) was obtained by grafting tertiary butyl amine and octanoyl groups on the pullulan backbone as cationic and hydrophobic moieties, respectively. The structural characteristics of the modified polymer were investigated by FT-IR and 1H and 13C NMR spectroscopy. The self-association ability in aqueous solution of DBAP-PO was studied by viscosity and fluorescence methods. The intrinsic viscosity of the polymer was determined by Wolf model. The critical aggregation concentration (CAC) value of 0.028 g/dL, determined by fluorescence measurements in the presence of pyrene, was confirmed by capillary viscosimetry and dynamic laser scattering (DLS). Dialysis method was used to demonstrate the capacity of the pullulan derivative to form spherical nanoparticles (d ~ 200 nm) loaded with model drug, sodium diclofenac (DF) (74% entrapment efficiency). The DF release was sustained and pH-dependent. In vitro cytotoxicity as well as morphological studies conducted on the human skin fibroblasts showed that DBAP-PO/DF nanoparticles do not exhibit cytotoxic effects at the pharmacologically relevant concentration of DF, maintaining the typical morphology of the cells.
Asunto(s)
Portadores de Fármacos , Glucanos/química , Nanopartículas/administración & dosificación , Cationes , Células Cultivadas , Diclofenaco/administración & dosificación , Diclofenaco/farmacocinética , Evaluación Preclínica de Medicamentos , Liberación de Fármacos , Fibroblastos/efectos de los fármacos , Glucanos/administración & dosificación , Glucanos/toxicidad , Humanos , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Estructura Molecular , Nanopartículas/química , Nanopartículas/toxicidad , Resonancia Magnética Nuclear Biomolecular , Espectroscopía Infrarroja por Transformada de Fourier , Tensoactivos/administración & dosificación , Tensoactivos/química , Tensoactivos/toxicidad , Viscosidad , AguaRESUMEN
A 2 × 3 factorial design experiment was conducted to examine the effects of reducing dietary crude protein (CP) concentration and/or supplementation with zinc oxide (ZnO) or laminarin on faecal scores (FS) and the large intestinal microbiota post-weaning (PW). One hundred and forty-four pigs were assigned to (T1) 21% standard CP diet (SCP); (T2) SCP + ZnO (SCP ZnO); (T3) SCP + laminarin (SCP LAM); (T4) 18% low CP diet (LCP); (T5) LCP + ZnO (LCP ZnO); and (T6) LCP + laminarin (LCP LAM; n = 8 replicates/treatment). The LCP diet had no effect on FS (p > .05), it increased two measures of alpha diversity, reduced Bacteroidetes and increased Enterobacteriaceae and Helicobacteraceae in the colon relative to the SCP diet (p < .05). ZnO supplementation reduced FS and increased Ruminococcaceae compared with unsupplemented pigs (p < .05). ZnO supplementation increased the genera Frisingicoccus (p < .001), Lachnoclostridium (p < .05) and Peptoclostridium (p < .05) in the colon and reduced total caecal volatile fatty acids (VFA) concentrations compared with the unsupplemented and laminarin-supplemented pigs. Laminarin supplementation reduced FS compared with unsupplemented pigs but had no major effect on the microbiota compared with the unsupplemented pigs. There were CP concentration × additive interactions on both Firmicutes and Proteobacteria. Firmicutes were increased in the LCP ZnO group compared with the LCP group, but there was no difference between the SCP groups. Proteobacteria were reduced in the LCP ZnO group compared with the LCP and LCP LAM groups (p < .05), but there was no difference between the SCP groups. In conclusion, reducing CP did not improve FS; it increased the relative abundance of Enterobacteriaceae; however, it also increased bacterial diversity. Supplementation with ZnO and laminarin improved FS, although all groups had scores within the healthy range. ZnO altered the large intestinal microbiota and VFA concentrations; however, laminarin did not enhance these parameters, suggesting these compounds have differing modes of action.
Asunto(s)
Proteínas en la Dieta/administración & dosificación , Suplementos Dietéticos , Heces/química , Microbioma Gastrointestinal/efectos de los fármacos , Glucanos/farmacología , Porcinos/microbiología , Óxido de Zinc/farmacología , Alimentación Animal/análisis , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Dieta/veterinaria , Glucanos/administración & dosificación , Óxido de Zinc/administración & dosificaciónRESUMEN
This study examined the effects of dietary supplementation with laminarin or chitosan on colonic health in pigs challenged with dextran sodium sulphate (DSS). Weaned pigs were assigned to: (1) a basal diet (n = 22); (2) a basal diet + laminarin (n = 10); and (3) a basal diet + chitosan (n = 10). On d35, the basal group was split, creating four groups: (1) the basal diet (control); (2) the basal diet + DSS; (3) the basal diet + laminarin + DSS; and (4) the basal diet + chitosan + DSS. From d39-42, the pigs were orally challenged with DSS. On d44, colonic tissue/digesta samples were collected. The basal DSS group had reduced growth, higher pathology score and an increased expression of MMP1, IL13 and IL23 compared with the controls (p < 0.05); these parameters were similar between the DSS-challenged groups (p > 0.05). In the basal DSS group, the relative abundance of beneficial taxa including Prevotella and Roseburia were reduced while Escherichia/Shigella were increased, compared with the controls (p < 0.05). The relative abundance of Escherichia/Shigella was reduced and the molar proportions of acetate were increased in the laminarin DSS group compared with the basal DSS group (p < 0.01), suggesting that laminarin has potential to prevent pathogen proliferation and enhance the volatile fatty acid profile in the colon in a porcine model of colitis.
Asunto(s)
Quitosano/farmacología , Colitis/prevención & control , Suplementos Dietéticos , Glucanos/farmacología , Mucosa Intestinal/efectos de los fármacos , Polisacáridos/farmacología , Sustancias Protectoras/farmacología , Animales , Quitosano/administración & dosificación , Colitis/inducido químicamente , Dextranos , Modelos Animales de Enfermedad , Glucanos/administración & dosificación , Masculino , Polisacáridos/administración & dosificación , Sustancias Protectoras/administración & dosificación , Distribución Aleatoria , PorcinosRESUMEN
Although viruses represent a major threat for cultured fish worldwide, the commercialization of vaccines capable of providing effective and long-lasting protection is still lacking for most of these viral diseases. In this situation, the use of supplemented diets could be a suitable strategy to increase the immune status of the fish and reduce the impact of viral pathogens. Among possible immunostimulants that could be included in these functional feeds, some studies have previously shown that certain ß-glucans can significantly increase certain immune parameters of fish and reduce the impact of viral diseases. However, the mechanisms through which ß-glucans exert their activity have not been fully elucidated yet. In the current study, we have studied the immune response of different tissues to viral haemorrhagic septicaemia virus (VHSV) in rainbow trout fed with a non-supplemented control diet as well as in fish fed a commercial functional aquafeed (Protec™, Skretting) containing ß-glucans, vitamin C, vitamin E and zinc. For this, after 30 days of feeding the fish with one of the two diets, they were subsequently infected with VHSV by bath or mock-infected. After 2 or 6 days post-infection, fish were sacrificed and the levels of transcription of different immune genes such as IgM, IgT, IgD, Mx, interferon γ (IFN γ) and perforin studied in different tissues (kidney, gut and gills). Additionally, the levels of natural IgMs in serum were also determined. Our results demonstrate that fish fed the functional diet were capable of mounting an increased IgM, IgT, IgD and Mx transcriptional response to the virus. Additionally, these fish also showed increased levels of natural IgMs in serum. These results reveal a previously undescribed effect of functional diets on fish Ig production and point to Protec™ as an adequate diet to be incorporated in holistic programs aimed at mitigating the effect of viral diseases.
Asunto(s)
Proteínas de Peces/genética , Expresión Génica/inmunología , Septicemia Hemorrágica Viral/inmunología , Novirhabdovirus/fisiología , Oncorhynchus mykiss/inmunología , Transcripción Genética/inmunología , Alimentación Animal/análisis , Animales , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/metabolismo , Dieta/veterinaria , Suplementos Dietéticos/análisis , Proteínas de Peces/metabolismo , Glucanos/administración & dosificación , Glucanos/metabolismo , Septicemia Hemorrágica Viral/genética , Vitamina E/administración & dosificación , Vitamina E/metabolismo , Vitaminas/administración & dosificación , Vitaminas/metabolismo , Zinc/administración & dosificación , Zinc/metabolismoRESUMEN
Background: Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier. Objective: The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea-predominant IBS (IBS-D). Methods: In this double-blind study, 60 patients were randomly assigned to receive XG + PPT + XOS or placebo for 28 days, then crossed over to the alternative treatment. Patients were followed for 60 days. Results: At Day 28, a significantly higher proportion of patients starting treatment with XG + PPT + XOS than placebo (87 vs 0%; p = 0.0019) presented normal stools (Bristol Stool Form Scale type 3-4). At Day 56, a significantly higher proportion of patients who crossed over to XG + PPT + XOS than placebo (93% vs 23%; p = 0.0001) presented normal stools. In the group allocated to receive XG + PPT + XOS after placebo, benefits of XG + PPT + XOS were maintained during follow-up. Subjective assessments of abdominal pain, bloating, quality of life and general health indicated significant improvement with XG + PPT + XOS over placebo. There were no related adverse events. Conclusion: XG + PPT + XOS effectively controlled diarrhoea and alleviated clinical symptoms in patients with IBS-D, and was well tolerated.
Asunto(s)
Demulcentes/uso terapéutico , Diarrea/tratamiento farmacológico , Glucanos/uso terapéutico , Síndrome del Colon Irritable/diagnóstico , Oligosacáridos/uso terapéutico , Proteínas de Guisantes/uso terapéutico , Xilanos/uso terapéutico , Dolor Abdominal/diagnóstico , Dolor Abdominal/tratamiento farmacológico , Dolor Abdominal/etiología , Adulto , Estudios Cruzados , Demulcentes/administración & dosificación , Método Doble Ciego , Quimioterapia Combinada , Diseño de Equipo/instrumentación , Femenino , Estudios de Seguimiento , Glucanos/administración & dosificación , Humanos , Síndrome del Colon Irritable/complicaciones , Síndrome del Colon Irritable/epidemiología , Síndrome del Colon Irritable/psicología , Masculino , Oligosacáridos/administración & dosificación , Proteínas de Guisantes/administración & dosificación , Placebos/administración & dosificación , Prebióticos/administración & dosificación , Prevalencia , Calidad de Vida , Rumanía/epidemiología , Seguridad , Resultado del Tratamiento , Xilanos/administración & dosificaciónRESUMEN
Background: Exposure to stressful stimuli dysregulates inflammatory processes and alters the gut microbiota. Prebiotics, including long-chain fermentable fibers and milk oligosaccharides, have the potential to limit inflammation through modulation of the gut microbiota. To determine whether prebiotics attenuate stress-induced inflammation and microbiota perturbations, mice were fed either a control diet or a diet supplemented with galactooligosaccharides, polydextrose and sialyllactose (GOS+PDX+SL) or sialyllactose (SL) for 2 weeks prior to and during a 6-day exposure to a social disruption stressor. Spleens were collected for immunoreactivity assays. Colon contents were examined for stressor- and diet- induced changes in the gut microbiome and metabolome through 16S rRNA gene sequencing, shotgun metagenomic sequencing and UPLC-MS/MS. Results: Stress increased circulating IL-6 and enhanced splenocyte immunoreactivity to an ex vivo LPS challenge. Diets containing GOS+PDX+SL or SL alone attenuated these responses. Stress exposure resulted in large changes to the gut metabolome, including robust shifts in amino acids, peptides, nucleotides/nucleosides, tryptophan metabolites, and B vitamins. Multiple B vitamins were inversely associated with IL-6 and were augmented in mice fed either GOS+PDX+SL or SL diets. Stressed mice exhibited distinct microbial communities with lower abundances of Lactobacillus spp. and higher abundances of Bacteroides spp. Diet supplementation with GOS+PDX+SL, but not SL alone, orthogonally altered the microbiome and enhanced the growth of Bifidobacterium spp. Metagenome-assembled genomes (MAGs) from mice fed the GOS+PDX+SL diet unveiled genes in a Bifidobacterium MAG for de novo B vitamin synthesis. B vitamers directly attenuated the stressor-induced exacerbation of cytokine production in LPS-stimulated splenocytes. Conclusions: Overall, these data indicate that colonic metabolites, including B vitamins, are responsive to psychosocial stress. Dietary prebiotics reestablish colonic B vitamins and limit stress-induced inflammation.
Asunto(s)
Antiinflamatorios/uso terapéutico , Azúcares de la Dieta/uso terapéutico , Microbioma Gastrointestinal/efectos de los fármacos , Oligosacáridos/uso terapéutico , Prebióticos/administración & dosificación , Estrés Psicológico/tratamiento farmacológico , Complejo Vitamínico B/metabolismo , Conducta Agonística , Animales , Bacterias/efectos de los fármacos , Bacterias/aislamiento & purificación , Bacterias/metabolismo , Colon/metabolismo , Colon/microbiología , Heces/microbiología , Microbioma Gastrointestinal/inmunología , Glucanos/administración & dosificación , Glucanos/farmacología , Interleucina-6/sangre , Masculino , Metagenómica , Ratones Endogámicos C57BL , Distribución Aleatoria , Ribotipificación , Método Simple Ciego , Conducta Social , Especificidad de la Especie , Estrés Psicológico/inmunología , Estrés Psicológico/metabolismo , Espectrometría de Masas en Tándem , Complejo Vitamínico B/uso terapéuticoRESUMEN
Aim: To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Patients & methods: Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. Results: At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. Conclusion: This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.
Asunto(s)
Antiinfecciosos/administración & dosificación , Glucanos/administración & dosificación , Extractos Vegetales/administración & dosificación , Própolis/administración & dosificación , Infecciones Urinarias/tratamiento farmacológico , Xilanos/administración & dosificación , Adulto , Femenino , Hibiscus/química , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Prevención Secundaria , Resultado del Tratamiento , Infecciones Urinarias/prevención & control , Adulto JovenRESUMEN
Circulating docosahexaenoic acid (DHA) and arachidonic acid (ARA) in total red blood cells (RBC) are considered indicators of fatty acid status. In this study, healthy term infants received study formula through 120 days of age. All study formulas had 17â¯mg DHA/100â¯kcal. Investigational formulas had 1) 25 g ARA/100â¯kcal and no added prebiotic blend (ARA-25; nâ¯=â¯29) or 2) 34â¯mg ARA/100 kcal and a prebiotic blend (1:1 ratio; 4â¯g/L) of polydextrose and galactooligosaccharides (PDX/GOS; nâ¯=â¯20). The control formula had 34â¯mg ARA/100â¯kcal and no added prebiotic blend (Control: nâ¯=â¯31). Fatty acids in total RBCs and plasma phospholipids (PPLs) at 120 days and buccal epithelial PLs at 14 and 120 days of age were assessed by capillary column gas chromatography. The calculated 90% confidence interval (CI) of each investigational formula relative to the Control for total RBC ARA (ARA-25: 93-105%; PDX/GOS: 96-110%) and total RBC DHA (ARA-25: 95-113%; PDX/GOS: 94-113%) fell within the pre-specified equivalence limit (85-118%), establishing study formula equivalence with respect to ARA and DHA. At day 120, total RBC and buccal epithelia PL ARA (µg/ml) were not significantly correlated (râ¯=â¯0.041; pâ¯=â¯0.732); correlation in total RBC and buccal epithelia PL DHA was low, albeit significant (râ¯=â¯0.324; pâ¯=â¯0.006). Consequently, buccal epithelial may not provide a suitable substitute for RBC when assessing fatty acid status and availability. The present RBC data suggest availability of DHA for central nervous system development and function is equivalent among infants receiving formulas that had 34 or 25â¯mg/100â¯kcal ARA and 17â¯mg/100â¯kcal DHA.
Asunto(s)
Ácido Araquidónico/sangre , Estatura/fisiología , Peso Corporal/fisiología , Ácidos Docosahexaenoicos/sangre , Fórmulas Infantiles/química , Ácido Araquidónico/administración & dosificación , Estatura/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Ácidos Docosahexaenoicos/administración & dosificación , Método Doble Ciego , Eritrocitos/química , Ácidos Grasos/sangre , Femenino , Glucanos/administración & dosificación , Humanos , Lactante , Fenómenos Fisiológicos Nutricionales del Lactante/efectos de los fármacos , Recién Nacido , Masculino , Mucosa Bucal/química , Oligosacáridos/administración & dosificación , Fosfolípidos/sangre , Estudios ProspectivosRESUMEN
The inhibitory effect of carboxymethyl pachyman (CMP) mixed with lotus seedpod oligomeric procyanidins (LSPC) in certain ratios against E. coli 10899 was determined. Added low concentration of LSPC could improve the antibacterial activity of CMP, and a significant synergistic effect could be observed between them, especially when the concentration of CMP was below its critical concentration (1.35 mg/mL). Then, the interaction between CMP and LSPC was characterized after mixing; the changes in spectral characteristics, thermal properties, crystallinity pattern, molecular weight, chain morphology and microrheological behaviour explained the influence of interaction on the structure of CMP and LSPC. The smaller molecular size, electrostatic interaction and stronger hydrophobic interaction might play important roles in improving the antibacterial activity of mixture. The dissociation constant (Kd) was determined to be 0.102±0.0008 mg/mL using MicroScale Thermophoresis (MST), and the micromorphology was observed by SEM. Therefore, this mixture might be an effective natural bacteriostat.
Asunto(s)
Antibacterianos/administración & dosificación , Glucanos/administración & dosificación , Lotus , Extractos Vegetales/administración & dosificación , Proantocianidinas/administración & dosificación , Wolfiporia , Antibacterianos/aislamiento & purificación , Antibacterianos/metabolismo , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Sinergismo Farmacológico , Escherichia coli/efectos de los fármacos , Escherichia coli/fisiología , Glucanos/metabolismo , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/metabolismo , Proantocianidinas/aislamiento & purificación , Proantocianidinas/metabolismo , Semillas , Difracción de Rayos XRESUMEN
BACKGROUND: A medical device containing xyloglucan-gelose-hibiscus-propolis (referred to hereafter as xyloglucan + gelose) acts as a mucosal barrier protector and urinary acidifier. The safety and efficacy of this device were investigated as adjuvant therapy to first-line antimicrobials for treatment of uncomplicated urinary tract infection (UTI) in adults. PATIENTS AND METHODS: In this multicentre, randomised, parallel group, double-blind, phase IV study, xyloglucan + gelose (n = 20) or placebo (n = 20) were administered orally in combination with an antimicrobial agent (e.g., ciprofloxacin) for 5 days, then alone for 5 days, then beginning on Day 30 of the study for 15 days per month for 2 months. RESULTS: Frequency of adverse events (AEs) was 5 and 45% in the xyloglucan + gelose and placebo groups respectively. All AEs were unrelated to study products. Xyloglucan + gelose reduced uroculture positivity (defined as a bacterial count ≥103 CFU/mL) from 100% of patients at baseline to 0% at Day 11, with recurrence in 3 patients (15%) by Day 76. Corresponding results with placebo were 100% uroculture positive patients at baseline reduced to 45% at Day 11, with recurrence in 14 patients (70%) by Day 76. Xyloglucan + gelose significantly reduced the frequency of urinary incontinence and urgency of micturition compared with placebo (both p < 0.05), with symptom resolution in all patients by Day 90. CONCLUSIONS: The xyloglucan + gelose medical device was safe, well tolerated, and it reduced bacteriological and symptomatic parameters in adults with uncomplicated UTI.
Asunto(s)
Antiinfecciosos/administración & dosificación , Quimioterapia Adyuvante/métodos , Glucanos/administración & dosificación , Infecciones Urinarias/tratamiento farmacológico , Xilanos/administración & dosificación , Adolescente , Adulto , Anciano , Ciprofloxacina/administración & dosificación , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Membrana Mucosa/efectos de los fármacos , Seguridad del Paciente , Recurrencia , Resultado del Tratamiento , Micción/efectos de los fármacos , Adulto JovenRESUMEN
The addition of fiber is one of the most important dietary means to relieve constipation through lifestyle modification. Polydextrose (PDX) has been reported in several studies to increase fecal bulk, soften stools, and increase the number of defecations. However, there are few studies on the effect of PDX on colonic transit time (CTT). Therefore, the aim of this study was to demonstrate the effect of PDX on CTT and other aspects of gastrointestinal function during two weeks (Day 1 to Day 14), preceded by a 2-week run-in period (Day -14 to Day -1). A total of 192 adults who were diagnosed with functional constipation per Rome III criteria were recruited for the study. Participants were randomized equally into 4 groups (12 g, 8 g, or 4 g of PDX or placebo per day). The primary endpoint was CTT, assessed using radio-opaque markers and abdominal X-rays on Day 0, the baseline; and Day 15, the end of the intervention. Secondary outcomes that were measured using inventories were the patient assessment of constipation symptoms and quality of life, bowel function index, relief of constipation, bowel movement frequency (BMF), stool consistency, degree of straining, and proportion of bowel movements. Ancillary parameters and harms were also evaluated. The recruited population was not sufficiently constipated (e.g., baseline values for CTT and BMF of 42 h and 8.7 BMF/week, respectively). Despite this limitation, our results demonstrated an increased number of bowel movements when supplemented with PDX at a dosage of 12 g per day for 2 weeks. This dosage also consistently improved the secondary outcomes that were measured using inventories at Day 15, compared with the baseline. No serious or significant adverse events were reported during the study.
Asunto(s)
Estreñimiento/terapia , Fibras de la Dieta/administración & dosificación , Suplementos Dietéticos , Tránsito Gastrointestinal/fisiología , Glucanos/administración & dosificación , Abdomen/diagnóstico por imagen , Adulto , Colon/fisiopatología , Estreñimiento/diagnóstico por imagen , Estreñimiento/fisiopatología , Defecación/fisiología , Método Doble Ciego , Femenino , Humanos , Masculino , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Chronic constipation (CC) remains a common gastrointestinal (GI) disorder that conveys a substantial healthcare burden. Expert guidelines recommend increasing fiber intake, yet the clinical evidence to support this needs strengthening for specific fibers. The aim was to evaluate changes in intestinal transit time and GI symptoms in CC patients who consumed polydextrose. In a randomized, double-blind, placebo-controlled trial, 128 adults with CC received 8 g or 12 g polydextrose, or placebo, daily for 4 weeks. Transit time, as primary outcome, was assessed by radiopaque marker distribution after 2-weeks intervention. Bowel habits, GI symptoms and quality of life (QOL) were assessed by questionnaire, including the Patient-Assessment of Constipation (PAC) Symptoms (SYM), and PAC-QOL. Following 2-weeks intervention, no reduction was seen in transit time in any group and following 2- or 4-weeks intervention, no improvements were seen in stool frequency or consistency in any group. After 2-weeks intervention with 8 g/day polydextrose an improvement was seen in the PAC-SYM rectal score (p = 0.041). After 4-weeks intervention both rectal (p = 0.049) and stool (p = 0.029) scores improved while improvement in the QOL satisfaction score did not reach significance (p = 0.071). Overall, the results suggest that 2-weeks consumption of 8 or 12 g/day polydextrose does not significantly improve physiological measures of gut function in CC adults. Longer term consumption may improve clinical measures, but further studies will be required to substantiate this.
Asunto(s)
Estreñimiento/terapia , Fibras de la Dieta/uso terapéutico , Suplementos Dietéticos , Tránsito Gastrointestinal , Glucanos/uso terapéutico , Intestinos/fisiopatología , Dolor Abdominal/etiología , Dolor Abdominal/prevención & control , Adulto , Anciano , Estreñimiento/fisiopatología , Fibras de la Dieta/administración & dosificación , Fibras de la Dieta/efectos adversos , Método Doble Ciego , Femenino , Glucanos/administración & dosificación , Glucanos/efectos adversos , Humanos , Análisis de Intención de Tratar , Masculino , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Calidad de Vida , Autoinforme , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Polydextrose (PDX) ingestion may increase the intestinal absorption of iron. This study evaluated the effects of 7.5% polydextrose supplementation on markers of iron uptake, transport and storage in partially gastrectomized rats. Half of a batch of 40 male Wistar rats (250 g) underwent Billroth II partial gastrectomy with anterior truncal vagotomy (GXT), while the other half underwent sham gastrectomy (SHAM). At 7 postoperative days, the animals were subdivided into four groups (n = 10): Sham Control and GXT Control (no polydextrose); Sham PDX and GXT PDX (with 7.5% PDX). The animals were euthanized after 60 day of PDX treatment. Organ weight, cecal pH, the characterization and quantification of short-chain fatty acids (SCFA), hematological parameters, hepatic iron content and the expression of ferroportin (FPT) in the jejunum, cecum, colon and liver were evaluated. PDX caused changes in the cecum of the supplemented animals, where there was a decrease in pH, increase in cecal wall and marked production of SCFA, especially acetic and propionic acids (p < 0.05). Hepatic iron levels were lower in GXT animals. PDX increased hemoglobin (HGB) values by 29.2% and hematocrit (HCT) by 55.8% in the GXT PDX group compared to the GXT Control group. The GXT PDX group had lower hepatic FPT expression (p < 0.05). PDX led to increased SCFA concentration in the supplemented animals. Considering that SCFAs play a central role in the increasing nutrients uptake, this mechanism may be involved in altering the hematology profile observed in these animals but not enough to reverse iron deficiency anemia in post-gastrectomy rats.